Alb-IFN
Alb-IFN Uses, Dosage, Side Effects, Food Interaction and all others data.
Albumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range of cancers. Human Genome Sciences modified interferon alpha to improve its pharmacological properties by using the company's proprietary albumin fusion technology. Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C. The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.
| Trade Name | Alb-IFN |
| Generic | Albinterferon Alfa-2B |
| Albinterferon Alfa-2B Other Names | alb-IFN, Albinterferon, Albinterferon Alfa-2B, Albuferon alpha, Albumin-interferon alpha |
| Type | |
| Formula | C3796H5937N1015O1143S50 |
| Weight | 85700.0 Da |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in hepatitis (viral, C).
How Alb-IFN works
Interferons belong to a family of proteins known as cytokines that occur naturally in the human body. Cytokines control cellular processes, such as cell growth, activation, migration and aging. While the precise mechanism of action for interferon alpha is not known, research has demonstrated direct antiviral activity in patients with diseases like hepatitis C, as well as immune-modulating and direct antitumor effects in certain types of cancer.
Innovators Monograph
You find simplified version here Alb-IFN
